142
Participants
Start Date
September 12, 2019
Primary Completion Date
December 31, 2023
Study Completion Date
June 30, 2024
Active JNJ-54175446
JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
Placebo
Matching placebo containing the same excipients
Addenbroooke's Hospital, Cambridge
Cardiff University Brain Research Imaging Centre, Cardiff
Queen Elizabeth University Hospital, Glasgow
The Maurice Wohl Clinical Neuroscience Institute, London
Warneford Hospital, Oxford
Collaborators (1)
Janssen Pharmaceuticals
INDUSTRY
CCTU-Core
OTHER